Inhibition of platelet-surface-bound proteins during coagulation under flow II: Antithrombin and heparin

• Published in: Biophysical journal Vol. 122; no. 1; pp. 230 - 240
• Main Authors: Miyazawa, Kenji, Fogelson, Aaron L., Leiderman, Karin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 03.01.2023; The Biophysical Society
• Subjects: Anticoagulants - pharmacology; Antithrombin III - metabolism; Antithrombin III - pharmacology; Antithrombins - metabolism; Antithrombins - pharmacology; Blood Coagulation - physiology; Heparin - chemistry; Heparin - pharmacology; Thrombin - metabolism
• ISSN: 0006-3495; 1542-0086; 1542-0086
• DOI: 10.1016/j.bpj.2022.10.038

Blood coagulation is a self-repair process regulated by activated platelet surfaces, clotting factors, and inhibitors. Antithrombin (AT) is one such inhibitor that impedes coagulation by targeting and inactivating several key coagulation enzymes. The effect of AT is greatly enhanced in the presence of heparin, a common anticoagulant drug. When heparin binds to AT, it either bridges with the target enzyme or induces allosteric changes in AT leading to more favorable binding with the target enzyme. AT inhibition of fluid-phase enzymes caused little suppression of thrombin generation in our previous mathematical models of blood coagulation under flow. This is because in that model, flow itself was a greater inhibitor of the fluid-phase enzymes than AT. From clinical observations, it is clear that AT and heparin should have strong inhibitory effects on thrombin generation, and thus we hypothesized that AT could be inhibiting enzymes bound to activated platelet surfaces that are not subject to being washed away by flow. We extended our mathematical model to include the relevant reactions of AT inhibition at the activated platelet surfaces as well as those for unfractionated heparin and a low molecular weight heparin. Our results show that AT alone is only an effective inhibitor at low tissue factor densities, but in the presence of heparin, it can greatly alter, and in some cases shut down, thrombin generation. Additionally, we studied each target enzyme separately and found that inactivation of no single enzyme could substantially suppress thrombin generation.